[ad_1]
The White House is considering the possibility of revoking the protection shield for anti-Covid vaccines produced in the United States, created in defense of intellectual property rights. This was reported by some American media. The move would allow other countries to replicate existing vaccines, thus responding to growing concern that only a handful of wealthy countries are entitled to disproportionate amounts of doses compared to global availability. House Speaker Nancy Pelosi would write to the White House stating that intellectual property is available to everyone.
The Covid vaccine shortage is a problem in much of the world but not in the United States, where President Joe Biden is already grappling with the opposite concern: how to handle surplus doses, given that by May, if not earlier, in USA. States, supplies will exceed demand. And the pressures, starting from Europe, are strong. Although for the moment – explains the New York Times – the intention of the White House would be to keep the leftover doses, despite the umpteenth call from the WHO: immediately donate at least 10 million vaccines to the international Covax program in favor of the countries poorer. But in Washington, beyond the outstretched hand shown by Biden during the European Council, the situation is viewed with caution. In fact, there are still too many uncertainties about the future and about when the pandemic will really be overcome and we can talk about herd immunity. Even more so since, despite the fact that the vaccination campaign travels at very high rates in America, the number of cases in all the states of the United States has risen again: 7% more in a week, with an average of 55,000 per day . And the number of hospitalizations and the number of victims also rises again, more than a thousand every 24 hours. With the forecasts in hand, Biden promised by the end of May to immunize the entire American adult population, about 260 million people. This is due to an ordered series of doses that, including Pfizer, Moderna, and Johnson & Johnson, could cover up to 400 million people, 70 million more than the entire US population. Choosing who to eventually overdose can become a political problem for the US administration, considering that despite the international Covax program there are at least 30 countries where not a dose has yet been administered, with three-quarters of the doses available. to only 10 countries.
REPRODUCTION RESERVED © Copyright ANSA
[ad_2]
